A new study finds a genetic change called ALK-fusion in a patient sample of a melanoma subtype called mucosal melanoma. When researchers treated a tumor grown from this sample with the drugs ...

Clinical Utility of ALK Fusion Detection by Liquid Biopsy. Cell-free DNA NGS detects common and novel ALK fusions in the plasma of lung cancer patients July 27, 2021 08:00 AM Eastern Daylight Time.

EML4-ALK is a fusion-type protein tyrosine kinase that is present in 4 to 5% of cases of non–small-cell lung cancer and is generated as a result of a small inversion within the short arm of ...

Anaplastic lymphoma kinase (ALK) gene encodes for a classical transmembrane tyrosine kinase receptor that belongs to the superfamily of insulin receptors and was first discovered in hematologic ...

In this special issue of CURE, we examine some of the latest developments in the treatment of ALK-positive non-small cell lung cancer (NSCLC). This subtype of lung cancer, representing about 5% of ...

Only 2 years after rearrangement of the ALK gene was proposed as a new target in lung cancer therapy, ... is activated not by mutation but by fusion with another gene." ...

In a scientific first, the fusion of two genes, ALK and EML4, has been identified as the genetic driver in an aggressive type of thyroid cancer, according to a study. These groundbreaking findings ...

Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene [published online ahead of print July 11, 2011]. Nature. 2007;448(7153):561-566.

Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non–small-cell lung cancers, representing 2 to 7% of such tumors.We explored the ...

In 2017, based on results from the ALEX (NCT02075840) trial, the FDA granted regular approval to alectinib for the treatment of ALK-positive mNSCLC as detected using an FDA-approved test. 10,17,18 ...